ɪn dʒˈænjuːˌɛɹi tˈuː θˈaʊzənd ˈeɪt, bˈeɪɚɹ ɪnfˈɔːɹmd hˈɛlθkɛɹ pɹəfˈɛʃənəlz ʌvðə mˈɑːɹkɪt wɪθdɹˈɔːl ʌvðə kˈɜːɹənt lˈɪkwɪd fˌɔːɹmjʊlˈeɪʃən ʌv sˈɑːɹɡɹɐmˌoʊstɪm.
In January 2008, Bayer informed healthcare professionals of the market withdrawal of the current liquid formulation of sargramostim.